Chong Kun Dang Pharmaceutical (185750) - Cash Flow Conversion Efficiency

Latest as of March 2026: 0.012x

Based on the latest financial reports, Chong Kun Dang Pharmaceutical (185750) has a cash flow conversion efficiency ratio of 0.012x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (₩12.32 Billion ≈ $8.35 Million USD) by net assets (₩1.03 Trillion ≈ $697.19 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See defensive interval ratio of Chong Kun Dang Pharmaceutical to measure how many days the company can operate on defensive assets alone.

Chong Kun Dang Pharmaceutical - Cash Flow Conversion Efficiency Trend (2016–2025)

This chart illustrates how Chong Kun Dang Pharmaceutical's cash flow conversion efficiency has evolved over time, based on yearly financial data.

Chong Kun Dang Pharmaceutical Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of Chong Kun Dang Pharmaceutical ranked by their cash flow conversion efficiency.

Company	Cash Flow Conversion Efficiency
Southern California Bancorp Common Stock NASDAQ:BCAL	0.015x
Canny Elevator Co Ltd SHE:002367	0.058x
Cikarang Listrindo Tbk PT JK:POWR	0.074x
Life & Banc Split Corp TO:LBS	-0.003x
Ackerstein Group Ltd TA:ACKR	0.022x
Mako Mining Corp Common Stock NASDAQ:MAKO	0.146x
Spire Global Inc NYSE:SPIR	0.000x
Worldline SA PA:WLN	0.037x

Annual Cash Flow Conversion Efficiency for Chong Kun Dang Pharmaceutical (2016–2025)

The table below shows the annual cash flow conversion efficiency of Chong Kun Dang Pharmaceutical from 2016 to 2025. For the full company profile with market capitalisation and key ratios, see Chong Kun Dang Pharmaceutical market capitalisation.

Year	Net Assets	Operating Cash Flow	Cash Flow Conversion Efficiency	Change
2025-12-31	₩1.01 Trillion ≈ $681.99 Million	₩67.36 Billion ≈ $45.65 Million	0.067x	-6.68%
2024-12-31	₩896.38 Billion ≈ $607.46 Million	₩64.29 Billion ≈ $43.57 Million	0.072x	-81.61%
2023-12-31	₩815.64 Billion ≈ $552.74 Million	₩318.16 Billion ≈ $215.61 Million	0.390x	+257.79%
2022-12-31	₩621.29 Billion ≈ $421.04 Million	₩67.73 Billion ≈ $45.90 Million	0.109x	+378.04%
2021-12-31	₩565.81 Billion ≈ $383.44 Million	₩12.90 Billion ≈ $8.74 Million	0.023x	-87.94%
2020-12-31	₩551.59 Billion ≈ $373.81 Million	₩104.32 Billion ≈ $70.70 Million	0.189x	+16.22%
2019-12-31	₩474.95 Billion ≈ $321.87 Million	₩77.29 Billion ≈ $52.38 Million	0.163x	+64.50%
2018-12-31	₩430.90 Billion ≈ $292.01 Million	₩42.63 Billion ≈ $28.89 Million	0.099x	-51.15%
2017-12-31	₩403.29 Billion ≈ $273.31 Million	₩81.67 Billion ≈ $55.35 Million	0.203x	+24.15%
2016-12-31	₩354.25 Billion ≈ $240.07 Million	₩57.79 Billion ≈ $39.16 Million	0.163x	--

About Chong Kun Dang Pharmaceutical

KO:185750 Korea Drug Manufacturers - Specialty & Generic

Market Cap

$634.87 Million

₩936.82 Billion KRW

Market Cap Rank

#11208 Global

#306 in Korea

Share Price

₩71100.00

Change (1 day)

-2.60%

52-Week Range

₩69800.00 - ₩97700.00

All Time High

₩207617.05